Shots:

• The US FDA has accepted the BLA under the 351(k) for CHS-1420 with an anticipated BsUFA date as Dec’2021
• The company plans to launch the CHS-1420 in the US on or after Jul 01- 2023 as per the terms of an agreement with AbbVie
• Coherus collaborated with Junshi in Feb’2021 to in-license toripalimab in the US and Canada. Additionally- Coherus will market Udenyca (pegfilgrastim) in the US and plans to launch biosimilars of Humira- Avastin and Lucentis in 2023- following their approval

 ­ Ref: GlobeNewswire | Image: Coherus